Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 7/20 | 0.64 |
| ▸ | PARP15 | Q460N3 | 6/20 | 0.64 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.53 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.43 |
| ▸ | PPARD | Q03181 | 3/20 | 0.43 |
| ▸ | LSS | P48449 | 1/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.40 |
| ▸ | ACACA | Q13085 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL927683 | 0.84 | PARP10 (0.68) | PARP10PARP15SCN9APARP2FFAR4 | |
| SCHEMBL1856415 | 0.81 | PARP10 (0.64) | PARP10PARP15SCN9APARP2FFAR4 | |
| SCHEMBL5057136 | 0.80 | KDM4E (0.53) | PARP10PARP15FFAR4FFAR1 | |
| SCHEMBL21123272 | 0.79 | LSS (0.64) | PARP10PARP15SCN9APARP2FFAR4 | |
| SCHEMBL927718 | 0.78 | PARP10 (0.61) | PARP10PARP15SCN9APARP2FFAR4 | |
| SCHEMBL5264249 | 0.77 | MAOB (0.43) | PARP10PARP15FFAR4FFAR1PPARD | |
| SCHEMBL2100809 | 0.76 | CPS1 (0.56) | — | |
| SCHEMBL29859365 | 0.76 | CPS1 (0.56) | — | |
| SCHEMBL22286220 | 0.76 | MAOB (0.44) | PARP10PARP15LSS | |
| SCHEMBL14901056 | 0.75 | PARP10 (0.55) | PARP10PARP15SCN9APARP2FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200247800-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247800-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS | NOX1, CYBB, NOX4 | PARP10 885/4885PARP15 938/4885SCN9A 1917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.